Related Experiment Video
Updated: Aug 7, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas
Rosaria Maddalena Ruggeri1, Salvatore Sciacchitano, Enrica Vitarelli
1Sezione di Endocrinologia, Dipartimento Clinico-Sperimentale di Medicina e Farmacologia, Policlinico Universitario, Messina, Italy.
Context:
Chemoresistance is due to the expression of multidrug-resistance proteins (MRPs). Cyclooxygenase 2 (COX2), a key enzyme in prostaglandins synthesis, upregulates MRP1. MRP1 is overexpressed in medullary thyroid carcinomas (MTCs), but it is not involved in resistance to doxorubicin and cisplatin, which are commonly used in MTC treatment. MRP2 is specifically involved in resistance to both chemotherapeutic agents, but no data exist on the expression of MRP2 and COX2 in MTC.
Objective:
To evaluate MRP2 and COX2 expressions in MTC.
Design:
We analyzed immunohistochemical expression of MRP2 and COX2 in 12 MTCs and in 6 lymph node metastases. Results were correlated with pTNM and clinical stage.
Results:
MRP2 and COX2 expressions were observed only in tumor samples and metastases. Nine MTCs, all pTNM stage T4, were positive for MRP2, whereas 3 MTCs, pTNM stages T2 and T3, were unreactive for MRP2. Six metastatic MTCs at stage T4 showed higher proportion of MRP2+ cells, compared with primary tumors. All 12 MTCs were positive for COX2. Three MTCs, pTNM stage T2 and T3, showed COX2 positivity in all cells. The proportion of COX2+ cells decreased with increased pTNM stage. Four out of 6 metastatic MTCs, stage T4, showed a lower proportion of COX2+ cells, compared with primary tumors. The proportion of MRP2+ cells was inversely related to the proportion of COX2+ cells.
Conclusions:
MRP2 and COX2 expression correlated with pTNM stage. High MRP2 and low COX2 expression may explain resistance to doxorubicin and cisplatin, which is observed in advanced stage MTC. Evaluation of the expression pattern of these 2 proteins may be useful to predict chemosensitivity of these types of tumors.
Insights
Multidrug-resistance protein 2 (MRP2) and cyclooxygenase 2 (COX2) expression in medullary thyroid carcinoma (MTC) correlates with tumor stage. High MRP2 and low COX2 may predict resistance to chemotherapy in advanced MTC.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Chemoresistance in medullary thyroid carcinoma (MTC) is linked to multidrug-resistance proteins (MRPs).
- Cyclooxygenase 2 (COX2) upregulates MRP1, but MRP2's role in MTC chemoresistance is unknown.
- MRP1 is overexpressed in MTC but not linked to doxorubicin/cisplatin resistance, unlike MRP2.
Purpose of the Study:
- To investigate the expression of MRP2 and COX2 in medullary thyroid carcinoma.
- To correlate MRP2 and COX2 expression with pTNM staging and clinical stage in MTC.
Main Methods:
- Immunohistochemical analysis of MRP2 and COX2 expression in 12 MTC primary tumors and 6 lymph node metastases.
- Correlation of protein expression with pTNM and clinical stage.
Main Results:
- MRP2 and COX2 were detected in MTC tumors and metastases.
- MRP2 expression was higher in advanced pTNM stage T4 MTCs and metastases.
- COX2 expression was higher in earlier stages (T2-T3) and decreased with advanced stage; MRP2 and COX2 showed inverse correlation.
Conclusions:
- MRP2 and COX2 expression levels correlate with pTNM stage in MTC.
- Elevated MRP2 and reduced COX2 expression may contribute to chemoresistance in advanced MTC.
- Assessing MRP2 and COX2 expression patterns could help predict MTC chemosensitivity.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
